CL2020003300A1 - Nuevos moduladores de lxr con resto molecular de núcleo bicíclico. - Google Patents

Nuevos moduladores de lxr con resto molecular de núcleo bicíclico.

Info

Publication number
CL2020003300A1
CL2020003300A1 CL2020003300A CL2020003300A CL2020003300A1 CL 2020003300 A1 CL2020003300 A1 CL 2020003300A1 CL 2020003300 A CL2020003300 A CL 2020003300A CL 2020003300 A CL2020003300 A CL 2020003300A CL 2020003300 A1 CL2020003300 A1 CL 2020003300A1
Authority
CL
Chile
Prior art keywords
lxr
molecular moiety
new modulators
bicyclic nucleus
bicyclic
Prior art date
Application number
CL2020003300A
Other languages
English (en)
Inventor
Ulrich Deuschle
Christian Gege
Eva Hambruch
Claus Kremoser
Olaf Kinzel
Manfred Birkel
Original Assignee
Phenex Fxr Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Fxr Gmbh filed Critical Phenex Fxr Gmbh
Publication of CL2020003300A1 publication Critical patent/CL2020003300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)

Abstract

La presente invención se relaciona con compuestos bicíclicos (por ej. indoles) que contienen un grupo sulfonilo, los cuales se unen al receptor X del hígado (LXR? y/o LXR?) y actúan preferiblemente como agonistas inversos de LXR.
CL2020003300A 2018-06-28 2020-12-18 Nuevos moduladores de lxr con resto molecular de núcleo bicíclico. CL2020003300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18180450 2018-06-28

Publications (1)

Publication Number Publication Date
CL2020003300A1 true CL2020003300A1 (es) 2021-07-02

Family

ID=62947921

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003300A CL2020003300A1 (es) 2018-06-28 2020-12-18 Nuevos moduladores de lxr con resto molecular de núcleo bicíclico.

Country Status (27)

Country Link
US (3) US11618747B2 (es)
EP (1) EP3814331B9 (es)
JP (1) JP7214086B2 (es)
KR (1) KR102678581B1 (es)
CN (1) CN112689630A (es)
AR (1) AR117599A1 (es)
AU (1) AU2019293727B2 (es)
BR (1) BR112020026405A2 (es)
CA (1) CA3104956C (es)
CL (1) CL2020003300A1 (es)
DK (1) DK3814331T3 (es)
EA (1) EA202092821A1 (es)
ES (1) ES2956045T3 (es)
FI (1) FI3814331T3 (es)
HU (1) HUE063538T2 (es)
IL (2) IL310623A (es)
LT (1) LT3814331T (es)
MX (1) MX2020014258A (es)
PH (1) PH12020552269A1 (es)
PL (1) PL3814331T3 (es)
PT (1) PT3814331T (es)
PY (1) PY1950412A (es)
SI (1) SI3814331T1 (es)
SM (1) SMT202300334T1 (es)
TW (1) TWI748194B (es)
UY (1) UY38283A (es)
WO (1) WO2020002611A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118791407A (zh) 2018-05-22 2024-10-18 奥索生物公司 亚磺酰基氨基苯甲酰胺以及磺酰基氨基苯甲酰胺衍生物
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
US20230159502A1 (en) * 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4126863A1 (en) 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2024097897A1 (en) * 2022-11-03 2024-05-10 Orsobio, Inc. Lxr modulators with bicyclic core moiety for treating dyslipidemias

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
JPH06145150A (ja) 1992-11-09 1994-05-24 Kyowa Hakko Kogyo Co Ltd イミダゾール誘導体
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
AU4967797A (en) 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Benzofuran derivatives
WO1998057931A2 (en) 1997-06-19 1998-12-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
PL198030B1 (pl) 1997-10-24 2008-05-30 Nissan Chemical Ind Ltd Związek sulfamoilowy oraz rolniczy i ogrodniczy fungicyd
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
AU9619301A (en) 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
BR0115102B1 (pt) 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
US6503907B2 (en) * 2000-11-28 2003-01-07 Hoffmann-La Roche Inc. Indole and dihydroindole derivatives
BR0116323A (pt) 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
WO2003082802A1 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Acid and ester compounds and methods of using the same
DE60309598T2 (de) 2002-06-24 2007-09-13 Schering Corp. Als histamin-h3-antagonisten geeignete indolderivate
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
GB0323845D0 (en) * 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
BRPI0507626A (pt) * 2004-02-11 2007-07-03 Irm Llc compostos e composiçoes como moduladores de lxr
WO2005085188A2 (en) 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
PT1756096E (pt) * 2004-05-03 2009-10-16 Hoffmann La Roche Derivados de indolilo como moduladores do receptor x do fígado
WO2005113499A1 (ja) * 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
AU2005271737A1 (en) * 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
WO2006109633A1 (ja) * 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
BRPI0620386A2 (pt) 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
ATE526327T1 (de) 2006-07-06 2011-10-15 Abbott Healthcare Products Bv Azaindolderivate mit einer kombination eines teilweisen agonismus am nikotinischen acetylcholinrezeptor und einer inhibierung der dopaminwiederaufnahme
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
EP2155724A1 (en) 2007-03-23 2010-02-24 Abbott GmbH & Co. KG Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CN101641348B (zh) 2007-03-30 2014-09-10 霍夫曼-拉罗奇有限公司 咪唑烷酮衍生物
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
EP2197842B1 (en) 2007-08-29 2012-05-23 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
CA2697500A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CA2705586A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP2731436B1 (en) 2011-07-15 2017-03-08 VIIV Healthcare UK Limited 2-(pyrrolo[2,3-b]pyridine-5-yl)-2-(t-butoxy)-acetic acid derivatives as hiv replication inhibitors for the treatment of aids
WO2013028999A1 (en) 2011-08-24 2013-02-28 The Trustees Of Columbia University In The City Of New York Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders
MY192815A (en) 2011-12-22 2022-09-09 Connexios Life Sciences Pvt Ltd Derivatives of aza adamantanes and uses thereof
KR20130142801A (ko) 2012-06-20 2013-12-30 안국약품 주식회사 １１β－ＨＳＤ１ 효소의 억제활성을 갖는 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
WO2014065575A1 (ko) * 2012-10-25 2014-05-01 주식회사유한양행 4,5-다이하이드로-1h-피라졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
WO2014085453A2 (en) 2012-11-29 2014-06-05 The Scripps Research Institute Small molecule lxr inverse agonists
EP2968275B1 (en) * 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
EP2990403A1 (en) 2014-08-29 2016-03-02 Novartis Tiergesundheit AG Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics
JP2018500388A (ja) 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109415363B (zh) 2016-05-18 2021-07-20 罗格斯，新泽西州立大学 用于治疗代谢疾病和癌症的新的线粒体解偶联剂
UY37659A (es) * 2017-04-10 2018-10-31 Phenex Fxr Gmbh Moduladores del receptor x del hígado (lxr)
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
CN118791407A (zh) 2018-05-22 2024-10-18 奥索生物公司 亚磺酰基氨基苯甲酰胺以及磺酰基氨基苯甲酰胺衍生物
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
WO2020257283A1 (en) 2019-06-18 2020-12-24 Mitopower Llc Nicotinyl riboside compounds and their uses
WO2024097897A1 (en) 2022-11-03 2024-05-10 Orsobio, Inc. Lxr modulators with bicyclic core moiety for treating dyslipidemias

Also Published As

Publication number Publication date
US20210147398A1 (en) 2021-05-20
CA3104956A1 (en) 2020-01-02
CA3104956C (en) 2023-11-28
IL310623A (en) 2024-04-01
MX2020014258A (es) 2021-05-27
KR102678581B1 (ko) 2024-06-25
PL3814331T3 (pl) 2023-11-13
HUE063538T2 (hu) 2024-01-28
UY38283A (es) 2020-01-31
EP3814331B1 (en) 2023-06-14
LT3814331T (lt) 2023-08-10
FI3814331T3 (fi) 2023-08-23
PT3814331T (pt) 2023-07-04
IL279722B1 (en) 2024-03-01
CN112689630A (zh) 2021-04-20
PH12020552269A1 (en) 2021-07-19
BR112020026405A2 (pt) 2021-04-06
IL279722A (en) 2021-03-01
TW202019907A (zh) 2020-06-01
US12291523B2 (en) 2025-05-06
WO2020002611A1 (en) 2020-01-02
TWI748194B (zh) 2021-12-01
DK3814331T3 (da) 2023-08-14
NZ772148A (en) 2024-05-31
KR20210025636A (ko) 2021-03-09
PY1950412A (es) 2021-10-27
ES2956045T3 (es) 2023-12-12
SI3814331T1 (sl) 2023-08-31
US11618747B2 (en) 2023-04-04
EP3814331B9 (en) 2023-08-09
EP3814331A1 (en) 2021-05-05
EA202092821A1 (ru) 2021-05-21
IL279722B2 (en) 2024-07-01
AR117599A1 (es) 2021-08-18
JP7214086B2 (ja) 2023-01-30
US20240317726A1 (en) 2024-09-26
US20230357214A1 (en) 2023-11-09
SMT202300334T1 (it) 2023-11-13
US11970484B2 (en) 2024-04-30
JP2021528451A (ja) 2021-10-21
AU2019293727B2 (en) 2022-06-30
AU2019293727A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
UY38283A (es) Nuevos moduladores de lxr con resto molecular de núcleo bicíclico
CL2020001546A1 (es) Compuestos de 4-azaindol.
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
PY1909256A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
ES3064093T3 (en) Antagonists of the muscarinic acetylcholine receptor m4
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
UY37310A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2017001185S1 (es) Automovil
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
MX2017006530A (es) Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
MX368167B (es) Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2015013223A (es) Sintesis y composicion de grupos de enlace de aminoacidos conjugados con compuestos usados para la toma de imagenes dirigida de tumores.
CL2018000696A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
UY37410A (es) Antagonistas de trpv4
CR20190392A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2019002873A1 (es) Moduladores del receptor x del hígado (lxr).
AR104174A1 (es) Oxadiazoles sustituidos con deuterio